Health & Bio
Cytokinetics' aficamten meets Phase 3 goal in non-obstructive HCM
ACACIA-HCM trial success on KCCQ-CSS and peak VO2 (p=0.021, p=0.003). First non-obstructive win challenges BMS Camzyos monopoly.
Primary sources · 2
ACACIA-HCM trial success on KCCQ-CSS and peak VO2 (p=0.021, p=0.003). First non-obstructive win challenges BMS Camzyos monopoly.
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.